Extracellular matrix ageing
Human evidence and active trials are visible in this field
26 human-evidence records · 2 active trials · 79 visible funding records · 5,979 universities
Longevity Patent Family
MIR-210-3P-INHIBITED STEM CELL THERAPEUTIC AGENT FOR STABILIZING IN-VITRO CULTURE OF STEM CELLS AND TREATING LIVER FIBROSIS
Source-linked patent metadata for MIR-210-3P-INHIBITED STEM CELL THERAPEUTIC AGENT FOR STABILIZING IN-VITRO CULTURE OF STEM CELLS AND TREATING LIVER FIBROSIS, including priority, record stage and longevity-topic connections.
Patent-family snapshot
Application publication visible
Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.
- Representative publication
- WO2026192413A1
- Earliest priority
- March 13, 2025
- Latest publication
- September 17, 2026
- Family publications
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Stem cells
Human evidence and active trials are visible in this field
51 human-evidence records · 17 active trials · 275 visible funding records · 5,850 universities
Organizations named in this family
Topics connected by metadata
Extracellular matrix ageing88% metadata match
Stem cells88% metadata match
What this family cites
- Earlier patent references
- 0
- Scientific and other non-patent references
- 0
- Priority dates represented
- 2
References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →